Galashiels firm ProStrakan wins EU drug clearance
Borders drug firm ProStrakan has been cleared to sell an anti-nausea patch in Europe.
The European Commission authorised the marketing of the company's Sancuso transdermal patch.
Sancuso will be marketed by the Galashiels-based firm in the UK, France, Germany, Spain, Italy and other EU countries.
The product is designed to prevent nausea and vomiting following chemotherapy.
Sancuso has already been approved in the US and some Asian countries.
ProStrakan, which was bought by Japanese pharmaceutical firm Kyowa Hakko Kirin (KHK) in 2011, said the patch would be suitable for patients who have difficulty swallowing tablets following chemotherapy or radiotherapy.
Chief executive Tom Stratford said: "Chemotherapy-induced nausea and vomiting is a distressing and debilitating condition for some cancer patients and we are pleased that Sancuso will now become available to clinicians and patients in Europe as well as the US.
"This product fits well with both ProStrakan's and KHK's oncology focus and will become a valuable part of our European portfolio of products."